Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

SummaryTo explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.

• Publication year

  2009

• Venue

  Investigational new drugs

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-008-9155-yPMID 18663410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• CGH microarrays and cancer.

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

  2007cited by this paper
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  2007cited by this paper
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

  2006cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

  2005cited by this paper
• Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy

  2004cited by this paper
• Current Perspectives on HER2 Testing: A Review of National Testing Guidelines

  2003cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• HER2/neu as a predictive factor in breast cancer.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors

  1999cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• HER2 expression in breast cancer: evidence gaps and challenges

  2025cites this paper
• Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

  2023cites this paper
• Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

  2020cites this paper
• OTT_A_240990 4385..4395

  2020influential citation
• A Novel Immunohistochemical Signature with the Quantification of HER2 Predicts the Complete Response in HER2-Positive Breast Cancer

  2019cites this paper
• Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting

  2018cites this paper
• Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type

  2017cites this paper
• HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis

  2016cites this paper
• Metastatic breast cancer: The Odyssey of personalization

  2016cites this paper
• Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes

  2015cites this paper
• Quantification of HER family receptors in breast cancer

  2015cites this paper
• Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer

  2015cites this paper
• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  2015cites this paper
• Reproducibility in the Assessment of HER2 DISH in Breast Cancer

  2015cites this paper
• High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.

  2014cites this paper
• HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.

  2014cites this paper
• High‐level ERBB2 gene amplification is associated with a particularly short time‐to‐metastasis, but results in a high rate of complete response once trastuzumab‐based therapy is offered in the metastatic setting

  2014cites this paper
• MicroRNAs: Are they indicators for prediction of response to radiotherapy in breast cancer?

  2013cites this paper
• Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

  2013cites this paper
• HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer

  2013cites this paper
• Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.

  2013cites this paper
• Human epidermal growth factor receptor (HER 2)/neu expression and gene amplification in colorectal cancer

  2011cites this paper
• Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.

  2011cites this paper
• Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway.

  2010cites this paper
• Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

  2010cites this paper
• Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

  2010cites this paper
• Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17

  2009cites this paper